Evidence map›Paper›PMID 26191780›Full record

Trial reportRedox report : communications in free radical research2016

Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.

Midori Nagase, Yorihiro Yamamoto, Yusuke Miyazaki, Hiide Yoshino

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Redox report : communications in free radical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 6 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  3. Pooled it
  4. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Edaravone's reno-protective effects against chronic heat-stress exposure.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  14. Article
  15. Review
  16. Prosaposin is a novel coenzyme Q10-binding protein.Journal of clinical biochemistry and nutrition · 2024
    Article
  17. Review
  18. Review
  19. Article
  20. Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Midori Nagasea School of Bioscience and Biotechnology , Tokyo University of Technology , 1404-1 Katakura-cho, Hachioji 192-0982 , Japan.
Yorihiro Yamamotoa School of Bioscience and Biotechnology , Tokyo University of Technology , 1404-1 Katakura-cho, Hachioji 192-0982 , Japan.
Yusuke Miyazakia School of Bioscience and Biotechnology , Tokyo University of Technology , 1404-1 Katakura-cho, Hachioji 192-0982 , Japan.
Hiide Yoshinob Yoshino Neurology Clinic , 3-3-16 Khonodai, Ichikawa 272-0827 , Chiba , Japan.
Tokyo University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVES AND

methodsCompared to age-matched healthy controls (n = 55), patients with amyotrophic lateral sclerosis (ALS) (n = 26) showed increased oxidative stress as indicated by a significantly increased percentage of oxidized coenzyme Q10 (%CoQ10) in total plasma coenzyme Q10, a significantly decreased level of plasma uric acid, and a significantly decreased percentage of polyunsaturated fatty acids in total plasma free fatty acids (FFA). Therefore, the efficacy of edaravone, a radical scavenger, in these ALS patients was examined. RESULTS AND DISCUSSION: Among 26 ALS patients, 17 received edaravone (30 mg/day, one to four times a week) for at least 3 months, and 13 continued for 6 months. Changes in revised ALS functional rating scale (ALSFRS-R) were significantly smaller in these patients than in edaravone-untreated ALS patients (n = 19). Edaravone administration significantly reduced excursions of more than one standard deviation from the mean for plasma FFA levels and the contents of palmitoleic and oleic acids, plasma markers of tissue oxidative damage, in the satisfactory progress group (ΔALSFRS-R ≥ 0) as compared to the ingravescent group (ΔALSFRS-R < -5). Edaravone treatment increased plasma uric acid, suggesting that it is an effective scavenger of peroxynitrite. However, edaravone administration did not decrease %CoQ10. Therefore, combined treatment with agents such as coenzyme Q10 may further reduce oxidative stress in ALS patients.

Indexed as

AgedAmyotrophic Lateral SclerosisAntipyrineBiomarkersEdaravoneFatty Acids, NonesterifiedFemaleFree Radical ScavengersHumansMaleMiddle AgedOxidation-ReductionOxidative StressPeroxynitrous AcidUbiquinoneUric AcidAntipyrineBiomarkerscoenzyme Q10EdaravoneFatty Acids, NonesterifiedFree Radical ScavengersPeroxynitrous AcidUbiquinoneUric AcidCoenzyme Q10 redox balanceEdaravone treatmentPeroxynitritePlasma free fatty acid compositionUric acid

Identifiers

PMID26191780
PMCPMC6837462
OpenAlexW1569713122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.